ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2556

Were Moll and Wright Right?

Sergio Schwartzman1, Madeline Epsten2, Jackie Szymonifka2, Stephen A. Paget3 and Lisa A. Mandl1, 1Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY, 2Rheumatology, Hospital for Special Surgery, New York, NY, 3Division of Rheumatology, Hospital for Special Surgery/Weill Cornell Medicine, New York, NY

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: classification criteria, Diagnostic criteria, psoriasis, Psoriatic arthritis and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 7, 2017

Title: Spondyloarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment Poster III: Outcomes, Outcome Measures, and Comorbidities

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: In 1973 Moll and Wright published the first paper on the classification criteria for Psoriatic Arthritis (PsA). In their pioneering work, these authors additionally described 5 subtypes of PsA: Oligoarticular (Oli), Polyarticular (Pol), Axial (Axi), DIP form (DIP) and Mutilans (Mut). The classification criteria have been replaced by the CASPAR criteria, and as a consequence there has been a loss of emphasis on the importance of the subtypes. Arguments for decreased significance have been based on claims that these subclasses may overlap, are not stable, and can change over time.

The hypothesis of this study is that with some exceptions, the Moll and Wright subtype classification criteria are stable over time and may have important therapeutic implications.

Methods: This was a retrospective cohort study. All patients with ICD-9 or ICD-10 PsA codes seen at a single center from January 1, 2013 through December 31, 2016 were identified. Patients who met CASPAR classification criteria and who had a Moll and Wright subtype identified and at least a 2 year follow up were studied and described. The distribution of continuous variables was assessed using the Shapiro-Wilk test. Categorical variables are summarized as frequency (percent).

Results: 104 patients were identified. Pertinent demographics are presented in table 1. Distribution and persistence of PsA subtype are presented in tables 2a and 2b. As there is evidence that the Oli and Pol subtypes may overlap and be influenced by therapy, a subanalysis combined these forms and the persistence was 87.5%.

Conclusion:  In this retrospective analysis, a striking persistence of the subtype of PsA was noted over time. This was particularly noted with the non-Oli forms of this disease. With the advent of therapeutically targeted therapy that may differentially affect the unique subtypes of PsA, this concept needs to be resurrected and perhaps modified. We would argue that Moll and Wright were right.

 


Disclosure: S. Schwartzman, None; M. Epsten, None; J. Szymonifka, None; S. A. Paget, None; L. A. Mandl, None.

To cite this abstract in AMA style:

Schwartzman S, Epsten M, Szymonifka J, Paget SA, Mandl LA. Were Moll and Wright Right? [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/were-moll-and-wright-right/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/were-moll-and-wright-right/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology